Nephrotect (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

Valine, together with other amino acids in Nephroprotect, serves as a building block for protein synthesis, supports tissue repair, and acts as a precursor for glutathione, enhancing antioxidant capacity and aiding metabolic processes that are often compromised in renal patients.

The dosage of Nephroprotect is determined by the prescribing clinician based on the patient’s renal function, nutritional status, and overall clinical condition. The prescriber sets the appropriate infusion rate and volume for each individual case.

Safety data for Nephroprotect in pregnancy or lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nephroprotect, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nephroprotect offers a comprehensive blend of essential amino acids in an intravenous formulation, whereas many alternative products may provide only partial amino acid profiles or be available in oral forms. The IV route ensures rapid delivery and precise dosing, which can be advantageous for patients with limited gastrointestinal absorption.

Nephroprotect must be stored at 2‑8 °C. Keep the solution refrigerated, protect it from light, and avoid freezing or shaking the container to maintain stability and sterility.

Nephroprotect is administered intravenously by a qualified healthcare professional. The solution is infused over a prescribed period, typically using an infusion pump, and the rate is adjusted according to the patient’s clinical response and laboratory monitoring.

Serious risks include anaphylactic reactions, severe electrolyte imbalances such as hyperkalemia, acute hepatic dysfunction, and renal stone formation. Patients should be closely monitored for signs of these events during and after infusion.

Nephroprotect should not be used in individuals with known hypersensitivity to any of its amino acid components, in patients with uncontrolled severe electrolyte disturbances, or in those receiving incompatible intravenous medications without appropriate monitoring.